NCPA names new officers for 2008-2009 period
ALEXANDRIA, Va. The National Community Pharmacists Association installed new officers and members of its executive committee for 2008 and 2009 at its 110th annual convention and trade exposition, which took place in Tampa, Fla., Oct. 11-15.
The organization’s House of Delegates also passed resolutions on subjects such as the sale of tobacco in pharmacies, illegal online drug sales, required residencies and compounding accreditation.
The organization appointed Holly Henry as its president, Joseph Harmison as president-elect, Mark Riley as secretary-treasurer and Keith Hodges, DeAnn Mullins, David Smith, Bill Osborn and Brian Caswell as vice presidents.
On the matter of tobacco sales in pharmacies, the House of Delegates? resolution encourages pharmacists to consider refraining from selling tobacco products.
FDA launches new Web page to provide safety information on prescription drugs
WASHINGTON The Food and Drug Administration announced Wednesday that it had launched a Web page to provide consumers and healthcare professionals with a single source of safety information about prescription drugs.
The page, www.fda.gov/cder/drugsafety.htm, provides links to information in categories such as drug labeling, drugs with risk evaluation and mitigation strategies, regulations and guidance documents and warning letters, import alerts, recalls, market withdrawals and safety alerts.
“By placing Web links to these up-to-date resources on a single page, we’re helping consumers and healthcare professionals find drug safety information faster and easier,” said Dr. Paul Seligman, associate director of safety policy and communication in the FDA’s Center for Drug Evaluation and Research. “This type of communication is aimed at helping consumers and healthcare professionals make well-informed decisions about medication use.”
FDA approves generic version of Epivir
WASHINGTON The Food and Drug Administration has granted tentative approval to Indian drug maker Macleods Pharmaceuticals’ generic version of GlaxoSmithKline’s HIV drug Epivir (lamivudine), FDA records show.
The drug would be available as 150 mg and 300 mg tablets, but cannot be marketed in the United States because of patent protection.
GSK’s patent for lamivudine will expire in 2010. Epivir had sales of $246.85 million in 2007, according to GSK financial records.